Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

End Of An Era? AstraZeneca Closes India Research Site Focused On Tropical Diseases

This article was originally published in PharmAsia News

Executive Summary

Stakeholders are asking if AstraZeneca remains committed to neglected tropical diseases after the company announces it will close its Indian research unit. The center was the last remaining big pharma basic research center in India.

You may also be interested in...



Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation

AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.

AstraZeneca India R&D Head Balganesh Tanjore On "Drug Hunting" In India To Be At Vanguard Of Innovation

Balganesh Tanjore heads AstraZeneca PLC's innovation efforts in India from the company's Bangalore-based R&D center. The senior scientist is known for his pioneering studies in the field of tuberculosis, having worked on several new compounds. Tanjore keeps a low profile but those in the field of medical research respect his contributions and appreciate his efforts in putting together a very robust innovative infrastructure in India. In a rare media intervew, Tanjore spoke to PharmAsia News' India bureau about "drug hunting" in India, including linking up with academic institutions for better solutions.

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel